New insights and updated guidelines for epigenome-wide association studies  by Chadwick, Lisa H. et al.
Neuroepigenetics 1 (2015) 14–19
Contents lists available at ScienceDirect
Neuroepigenetics
j ourna l homepage: www.e lsev ie r .com/ locate /nep igNew insights and updated guidelines for epigenome-wide
association studies☆Lisa H. Chadwick a, Akira Sawa b, Ivana V. Yang c, Andrea Baccarelli d, Xandra O. Breakeﬁeld e,
Hong-Wen Deng g, Dana C. Dolinoy f, M. Daniele Fallin h, Nina T. Holland i, E. Andres Houseman j,
Stavros Lomvardas k, Mahendra Rao l, John S. Satterlee m, Frederick L. Tyson n,
Pandurangan Vijayanand o, John M. Greally p,⁎
a Division of Extramural Research and Training, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA
b Department of Psychiatry, Johns Hopkins University, Baltimore, MD, USA
c Department of Medicine, University of Colorado Denver, Aurora, CO, USA
d Department of Environmental Health, Harvard School of Public Health, Boston, MA, USA
e Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
f Department of Environmental Health Sciences, University of Michigan, Ann Arbor, MI, USA
g Department of Biostatistics and Bioinformatics, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA
h Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
i Division of Environmental Health Sciences, School of Public Health, University of California Berkeley, Berkeley, CA, USA
j Department of Biostatistics, College of Public Health and Human Sciences, Oregon State University, Corvallis, OR, USA
k Department of Anatomy, University of California San Francisco, San Francisco, CA, USA
l Laboratory of Stem Cell Biology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA
m Division of Basic Neuroscience and Behavioral Research, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA
n Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA
o La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA
p Center for Epigenomics, Albert Einstein College of Medicine, Bronx, NY, USA
a b s t r a c ta r t i c l e i n f o☆ WorkshopparticipantDr. Arturas Petronis from the Cen
Health at the University of Toronto, Canada, preferred not
⁎ Corresponding author. Tel.: +1 17186781234; fax: +
E-mail address: john.greally@einstein.yu.edu (J.M. Gre
http://dx.doi.org/10.1016/j.nepig.2014.10.004
2214-7845/© 2014 The Authors. Published by Elsevier IncArticle history:
Received 13 October 2014






Genome-wideEpigenetic dysregulation in disease is increasingly studied as a potential mediator of pathophysiology. The
epigenetic events are believed to occur in somatic cells, but the limited changes ofDNAmethylation in studies
to date indicate that only subsets of the cells tested undergo epigenetic dysregulation. The recognition of this
subpopulation effect indicates the need for care in design and execution of epigenome-wide association stud-
ies (EWASs), paying particular attention to confounding sources of variability. Tomaximize the sensitivity of
the EWASs, ideally, the cell typemediating the disease should be tested, which is not always practical or eth-
ical in human subjects. The value of using accessible cells as surrogates for the target, disease-mediating cell
type has not been rigorously tested to date. In this review, participants in a workshop convened by the Na-
tional Institutes of Health update EWAS design and execution guidelines to reﬂect new insights in the ﬁeld.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Epigenetic regulatory mechanisms play a crucial role in normal
human development, in part by establishing and maintaining the
gene expression programs necessary for cells to perform their unique
functional roles. In recent years, there has been growing interest in
investigating whether changes in these epigenetic programs contrib-
ute to the development of a variety of complex human diseases. Sev-
eral lines of evidence suggest that this might be the case. Thesetre forAddiction andMental
to co-author this document.
1 7184301016.
ally).
. This is an open access article uninclude the potential for the epigenome to mediate environmental
inﬂuences (reviewed in Cortessis et al., 2012; Hou et al., 2012; Perera
& Herbstman, 2011; Reamon-Buettner et al., 2008) or the mainte-
nance ofmemory of events that occurred in thepast, includingprena-
tal exposures inﬂuencing adult disease susceptibility (reviewed in
Barouki et al., 2012; Gluckman et al., 2011; Warner & Ozanne,
2010; Waterland & Michels, 2007). The ﬁeld of cancer epigenomics
has established a precedent for the silencing or activation of genes
being causally involved in neoplasia (Dawson & Kouzarides, 2012;
Esteller, 2007), somatic events that are usually limited to the cells
or tissue in which the cancer arose, with a few notable exceptions
(Cui et al., 2003; Gaston et al., 2001). Unlike the genome, theder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
15L.H. Chadwick et al. / Neuroepigenetics 1 (2015) 14–19epigenome is inherently malleable from a biochemical perspective,
and the potential to reverse deleterious epigenetic events has been
seen as a major opportunity, especially in the treatment of cancer
(Grifﬁths & Gore, 2013; Popovic & Licht, 2012; Rius & Lyko, 2012).
The ﬁeld of epigenome-wide association studies (EWASs) is now
very active, testing awide variety of human diseases and other pheno-
types. These EWASs have almost all been based on the study of DNA
methylation, an epigenetic regulator that is less demanding in terms
of clinical sample acquisition than alternatives such as sequencing of
DNA from chromatin immunoprecipitation, whichmaps histone mod-
iﬁcations or other chromatin constituents. A consistent outcome of the
EWAS studies to date has been the observation ofmoderate changes in
DNA methylation between disease and normal groups, and not a
switch between fully unmethylated and methylated states at a given
genomic locus. As DNAmethylation exists in a binary state at a speciﬁc
location on an individual allele,moderate changes have to reﬂect allelic
and cell subpopulation changes between the tested groups, an epige-
netic mosaicism that may be of pathophysiological signiﬁcance if sub-
sets of cells can reasonably be proposed to mediate the organ’s
disease state.
This emerging observation of cell subpopulation effects has forced
a re-evaluation of howwe should approach EWAS design and execu-
tion. With limited effect sizes associated with the disease or pheno-
type, it is necessary to pay increased attention to other sources of
variability potentially affecting the study. It is also essential that we
invest our efforts in a cell type that is likely tomanifest the differences
sought. Epigenomic dysregulation associated with human disease is
generally thought of in terms of somatic rather than germline events,
raising the issue whether the cell type(s) mediating the disease (tar-
get cell type) needs to be sampled, or whether a more accessible sur-
rogate cell type can yield sufﬁciently useful information.
The inﬂuence of cell type on epigenetic variability is highlighted
by large-scale epigenomicmapping efforts such as that led by theNa-
tional Institutes of Health (NIH) Roadmap Epigenomics Program
(Bernstein et al., 2010). There are other inﬂuences on epigenome-
wide studies to consider, such as technical inﬂuences, DNA sequence
polymorphism, and human subject characteristics (age, sex, expo-
sure history), all potentially confounding the ability to recognize gen-
uine effects associated with a disease or phenotype and leading, in
some cases, to misinterpretation of the results obtained.
In this review, we describe the broader issue of rigorous EWAS de-
sign and execution, updating prior excellent EWAS overviews (Bell &
Spector, 2011; Mill & Heijmans, 2013; Rakyan et al., 2011; Satterlee
et al., 2010; Verma, 2012), with an emphasis on the speciﬁc issue of
the value of studies based on surrogate cell use, and deﬁne 3 areas of
research priority that could further improve our design and interpreta-
tion of EWASs.
Updated guidelines for rigorous EWASs
Taking a cue from the history of genome-wide association studies
(GWASs), it is essential that rigorous standards are developed for
EWASs, which are likely to be more complex than GWASs, involving
many different types of epigenetic regulatorymechanisms, cell types,
and likely confounding inﬂuences. As a starting point, we provide an
overview of updated suggested best practices for EWASs, described
below and in Fig. 1, building upon prior recommendations for how
best to design andperform such studies (Bell & Spector, 2011; Rakyan
et al., 2011; Satterlee et al., 2010; Verma, 2012).Begin with an explicit biological hypothesis: Linking epigenetic
changes to disease or phenotypic causation, or as amarker orme-
diator of environmental exposure, should be stated in terms of anexplicit hypothesis. Although there is clearly value to exploratory
or pilot studies to test whether a certain phenotype or condition
has any evidence for nonrandomly associated epigenetic changes,
when performing a deﬁnitive study, it is essential to deﬁne the
underlying hypothetical mechanism involving epigenetic pertur-
bation. Having such a clear hypothesis allows the experimental
design and, in particular, the analysis and interpretation to be fo-
cused productively. For example, the timing of sample collection
or the choice of cross-sectional versus longitudinal studies and
the rationale for choosing a speciﬁc surrogate cell type for study
will be dictated to a major extent by the underlying hypothesis.
Puriﬁed cell types are preferable for epigenetic studies: It is
highly desirable that single cell types are used where possible. Al-
though it has been appreciated for some time that different cell
types have distinctive epigenetic proﬁles (Shen et al., 2012; Varley
et al., 2013), it has recently been conﬁrmed that the presence of
different proportions of cell subtypes in mixed populations of
cells can generate distinctive DNA methylation proﬁles
(Houseman et al., 2012), which has been found for some loci to
explain up to 40% of DNA methylation differences between indi-
viduals (Adalsteinsson et al., 2012). If there is a systematic bias
in cell subpopulation composition between the groups of individ-
uals being tested (e.g., between disease states, exposures, or phe-
notypes), DNA methylation assays performed will identify
differences between groups, but these will not necessarily repre-
sent altered epigenetic patterns within each cell type associated
with the disease. It is therefore preferable that pure cell samples
be tested when feasible, often a difﬁcult issue when cell numbers
from puriﬁed cell samples yield less material than can usually be
tested in genome-wide assays. It should be recognized that
“pure” does not mean homogeneous in terms of function, so puri-
ﬁcation does not eliminate the possibility of cell subtype composi-
tion exerting an inﬂuence. However, the selection of puriﬁed cells
ensures that as similar cell types as possible are compared be-
tween groups and makes it easier for other groups to reproduce
the experiment, both valuable considerations.
If it is not possible to purify cells, it should be attempted to account
for subpopulation effects in statistical models, either through
analysis of the samples collected (for example, histological studies
to quantify cell proportions or measurement of differential white
blood cell count in leukocyte-based studies) or through the devel-
opment of new analytical techniques that use DNA methylation
signatures to measure cell subpopulation proportions (Houseman
et al., 2012). Examples of this kind of approach were published re-
cently (Guintivano et al., 2013; Liu et al., 2013), demonstrating a
major reduction in association signals after adjustment for
the estimated cell proportions in the blood samples tested, em-
phasizing both the potential for variability in cell subpopula-
tions to exert strong effects on the DNA methylation signals
as well as the potential for sophisticated analytical approaches
to account for these effects.
Target versus surrogate cell types: An underlying assumption in
many EWASs is that epigenetic changes associated with a partic-
ular disease are likely acquired in somatic cells during develop-
ment or during aging (as opposed to through the germline or
extremely early in development). It follows that these epigenetic
changes may not be observed in all cell types in the body. The
choice of cell type is thus of great importance in human disease
studies. The ideal situationwould be to acquire those cells directly
affected by or mediating the disease, cells we refer to as the target
cell type, puriﬁed to the greatest extent possible. For many dis-
eases, obtaining such samples can be very challenging. As an ex-
ample, target cell types in disorders of the central nervous
system generally can only be studied in postmortem specimens.
Fig. 1. On the left are shown components of an ideal EWAS design, with alternative approaches on the right that represent some of the compromises that often have to be made
when dealing with studies involving human subjects.
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modifying enzymesmaintain their activities in postmortem brain
(Monoranu et al., 2011), the experience with expression proﬁling
indicates that we need, at a minimum, to be alert to issues like
sample acquisition and storage, and for information about tissue
pH, agonal factors (Atz et al., 2007), and pharmacological treat-
ments. It should also be noted that even with more accessible or-
gans, procedures that are performed on adults to collect target
cells are often less frequently performed on children, a good ex-
ample being bronchoscopy of the lung and sampling of airway
epithelium.
Prompted by these difﬁculties and by the availability of existing
samples such as blood from cohorts of subjects with diseases of
interest and/or well-characterized environmental exposures, the
question arises whether surrogate cells, deﬁned as “nontarget”
readily accessible cell types, share the epigenetic dysregulation
of the target cell type in a disease (or other) state of interest and
are thus potentially informative for disease studies. There is no
clear answer to this question at present. What is apparent is that
there is a need for studies to testwhether such an approach is fea-
sible, potentially informative, and capable of generating enough of
a “signal” of disease association that can be discriminated from
the “noise” of the multiple variables that can confound these
studies.
Sources of variability need to be understood: There are many
potential sources of variability that can affect EWAS data interpre-
tation, including patient or disease issues (age (Heyn et al., 2012),
sex (Sarter et al., 2005), and medications (Gonzalez-Fierro et al.,
2011; Junien, 2006) or exposure histories), sample collectionissues, nucleic acid puriﬁcation protocols (Soriano-Tarraga et al.,
2013), inﬂuences inherent to the experimental assays performed,
and even the version and type of software analytical tools used to
process and interpret the data generated. To account for these in-
ﬂuences, it is recommended that metadata (data describing the
information collected and generated) also be collected systemati-
cally and comprehensively. At a minimum, variables known to af-
fect epigenetic marks such as age and sex must be collected as a
part of the metadata. In addition, technical variables associated
with experimental protocols also must be collected to account
for technical variability or “batch effects” that are present in
both array- and sequence-based data (Leek et al., 2010). If the
timing of an exposure is potentially critical in terms of a suscepti-
bility window, this information needs also to be collected. Finally,
extensive disease phenotype data collected at this stage can pro-
vide valuable insight into the epigenetic regulation of that disease
state. In the data analysis stage, these potential sources of variabil-
ity can be explored and their inﬂuences can be accounted for in
statistical modeling (Leek et al., 2010) to avoid misleading, arti-
factual results.
The role of underlying DNA sequence variability has to be de-
termined: It is now appreciated that DNA sequence is not
completely inert in terms of the capability to establish epigenetic
patterns locally. Some of these inﬂuences are reasonably intuitive,
such as the polymorphism of the target sequence for a DNA-
binding protein being associated with failure of its binding to
the site (Spivakov et al., 2012), whereas others aremechanistical-
ly less clear, such as single nucleotide polymorphisms (SNPs)
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2011) or over even greater genomic distances (Gibbs et al.,
2010; Liu et al., 2013). Unrecognized polymorphisms of the CGdi-
nucleotides tested in a DNA methylation study can also lead to
misleading results, prompting someanalytical approaches toﬁlter
out overlapping common SNPs (Wang et al., 2012). At a mini-
mum, self-reported ethnicity should be part of the metadata cap-
tured and balanced between groups as part of the study design, or
handled through analytic adjustment, recognizing that this infor-
mation is frequentlymisleading (Choudhry et al., 2007). Some an-
cestral information can be gleaned from the SNPs included
explicitly, as well as SNPs in probes, of microarray data such as
those from the Illumina 450 K microarray. Direct genotyping ap-
proaches using SNP microarrays (including ancestry-informative
markers) or even whole genome sequencing are preferable, as
this will allow more robust testing of the effect of sequence
variability.
Attention needs to be paid to the analytical resources and ap-
proaches:Given the sizes of the data sets generated, the complex-
ity of the information when combined with a full range of
metadata, and the broad range of alternatives in exploring these
data, it is essential that a comprehensive data analysis plan is as-
sembled and put in place with adequate hardware and expertise
resources before initiating these studies.
Deﬁne in advance how results will be interpreted: As men-
tioned earlier, it also needs to be deﬁned in advance of a project’s
initiationwhat will constitute ameaningful outcome to the study.
Although it is essential that the associations between epigenetic
variability and phenotype (disease or environmental factor) sur-
vive rigorous statistical testing, it is also recommended that the
results be evaluated in terms of biological plausibility. Statistically
robust resultsmay reasonably constitute a new insight but lack bi-
ological plausibility in terms of the starting hypothesis. Such cases
should be treated with a degree of skepticism and should be the
focus of especially careful testing of the results generated, as de-
scribed next.
Test the conclusions rigorously: All studies, whether positive or
negative in terms of the criteria above, need to undergo validation
following completion and analysis of the epigenome-wide assays.
It should be emphasized that epigenome-wide assays are inherent-
ly less quantitative and accurate than single-locus studies, so until2. It needs to be determinedwhether epigenetic variability occurs over time in the same ind
e comparable patterns of variability, and whether different individuals will have comparab
onsidered in parallel with the genetic variability between individuals that may be inﬂuentia
lly, the functional consequences of this epigenetic variability need also to be measured to usuch single-locus studies are performed, the results of the
epigenome-wide assays can only be regarded as preliminary and
suggestive. The values generated by the epigenome-wide study
shouldbe technically analyzed to verify that the assayswere consis-
tently generating values reﬂecting the underlying biological reality.
Such analysis should involve the use of a gold-standard approach
for a range of values, such as a sodium bisulphite sequencing ap-
proach for DNAmethylation, exploring a range of values generated
by the epigenome-wide assay. The loci found to be distinctive be-
tween experimental groups by the epigenome-wide assay should
also be tested individually using the gold-standard technique to
conﬁrm that these candidates are indeed distinctive epigenetically
between groups.
Finally, it is desirable that the results be replicated in a separate
cohort of individuals, whether as part of the original study
(Joubert et al., 2012) or as a separate project. These measures
will lend the study the necessary conﬁdence that the results will
continue to be reproducible and are reﬂective of genuine underly-
ing biological changes. Although independent replication is gen-
erally favored over a split sample approach, such independent
replication cohorts will be inherently more challenging to assem-
ble in EWASs than for GWASs, given the potential for the con-
founding variables of environment, genotype, and others
mentioned earlier to inﬂuence the results. This being the case, a
second, validation cohort will have to be studied as comprehen-
sively as the initial test cohort, blurring the lines between the
split and independent cohort paradigms.
Experiences need to be shared: Finally, in this young ﬁeld, it is
essential that all insights and experience be shared fully so that
the best practices, biological insights, and analytical approaches
are disseminated effectively and contribute to the continuous im-
provement of research design, analysis, and interpretation in the
ﬁeld. Even negative results or the effects of strong confounding
variables need to be documented to help guide subsequent stud-
ies and to ensure that subsequent epigenomic projects are de-
signed to be as rigorous as possible. Beginning at the stage of
obtaining consent for study participation, attention should be
paid to ensuring that DNA sequence data can be deposited into
appropriate NIH or other public databases (e.g., database of Geno-
types and Phenotypes, Gene Expression Omnibus) to make them
accessible to other investigators.ividual in the same cell type, whether different cells from that same individual will
le or distinctive patterns in terms of degree and the loci involved. This all has to
l, as well as environmental inﬂuences that can potentially modify the epigenome.
nderstand their signiﬁcance.
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The discussion above highlights deﬁciencies in our understanding
of inﬂuences that could affect EWASs and indicates that some foun-
dational studies may be needed to allow rational EWAS design.
There is a clear need to test whether surrogate cells can be used in
EWASs. A different cell type to the target cell type affected by the dis-
ease may have distinctive patterns of epigenetic regulatory marks
such as DNAmethylation (Varley et al., 2013) and chromatin constit-
uents (Shen et al., 2012), probably related causally to differences in
transcriptional patterns between the cell types. The issue to be tested
is whether, even in this different epigenetic background, the surro-
gate cell type has distinctive epigenetic patterns in subjects with
a disease of interest compared with subjects who do not have the
disease and whether these epigenetic changes are reﬂective of
those occurring in the target cell type. Even in a situation when the
disease-associated epigenetic differences in the surrogate cells are
not identical to those found in the target tissues, the ﬁnding of differ-
ences may still be of signiﬁcant value as a clinical application, such as
a diagnostic test or a biomarker of outcome or exposure. This is easier
to test in animal models, in which longitudinal studies can be per-
formed; different cell types can be readily sampled at necropsy; and
control can be exerted over environment, age, genotype, and the
timing of exposures. There is, however, no guarantee that the physi-
ological response of the animal predicts that of humans, so whether
the ﬁndings have human disease signiﬁcance remains uncertain
even after successful execution of the animal-based project (Seok
et al., 2013). These caveats aside, animal models have the potential
to provide us with valuable insight into how speciﬁc, controlled ex-
posures affect epigenetic marks in target and surrogate tissues.
The third area of emphasis is the need to understand epigenetic
variability, an emerging issue that needs to be taken into account in
EWASs, including those testing cell surrogacy. There are several
types of epigenetic variability to consider (Fig. 2), of which interindi-
vidual variability for epigenomic patterns for the same cell type is
only recently being recognized and studied (Gemma et al., 2013;
Yuen et al., 2009). Variability may occur over time with repeated
sampling of a speciﬁc cell type from an individual using a longitudinal
approach (intraindividual variability or “epigenetic drift” across
time). Temporal variability is a complicating factor in EWASs that is
not encountered in GWASs and because of the typical case-control
design represents a cross-sectional approach that, in individuals al-
readymanifesting the disease of interest, could be complicated by is-
sues of reverse causality.
At present, we do not know the extent of epigenomic variability,
the proportion of loci affected, where in the genome variability
tends to occur, whether early environmental exposures affect vari-
ability, whether this variability changes during the life of the subject,
or whether different cell types have differing patterns of variability. It
is clear that these issues need to be addressed so that researchers can
design EWASs appropriately, and to interpret reference data accu-
rately. For example, the goal of the NIH Roadmap Epigenomics Pro-
gram was to develop a resource of reference maps to characterize
cell type–deﬁned variability but not population-level variability or in-
dividual variability across time. Consequently, loci with low variabil-
ity cannot be distinguished from those with high variability, with
resulting problems interpreting these reference maps in terms of
conﬁdence for each locus.
Conclusions
The ﬁeld of EWASs is growing, with a broad range of diseases and
other phenotypes being studied in human subjects. Just as GWASs
evolved by consensus to adopt best practices, a similar processneeds to occur for epigenomic studies. In many respects, EWASs are
more complicated than GWASs in terms of the types and magnitude
of data generated, the somatic as opposed to typically germline na-
ture of the events, and the broader range of potential confounding
variables. The challenge for the ﬁeld of epigenomics and human dis-
ease is to deﬁne the best practices that will allow studies to be per-
formed that will prove robust to replication and reveal underlying
biological events involved in diseases, whether in directly affected
or surrogate cells.
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